Type Condition

Honolulu, HI

164 Clinical Paid Trials near Honolulu, HI

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CABA-201 for Inflammatory Myopathies

San Francisco, California
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 75

24 Participants Needed

AFNT-211 for Solid Tumors

San Francisco, California
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

Gene Therapy for ALS

San Francisco, California
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

20 Participants Needed

NisinZ® P for Oral Cancer

San Francisco, California
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

40 Participants Needed

GSK4524101 + Niraparib for Cancer

San Francisco, California
This trial is testing a new drug called GSK4524101 alone and with another drug called niraparib. It aims to find the highest safe dose and understand its effects, likely targeting cancer patients who need new treatment options. Niraparib is a drug taken by mouth that is used to maintain treatment in ovarian cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

135 Participants Needed

Myelin Repair Therapy for Multiple Sclerosis

San Francisco, California
The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with acute inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments. No reparative therapies exist for the treatment of acute demyelinating lesions. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at the University of California, San Francisco (UCSF). Following in vivo validation, an FDA IND exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577. This study seeks to follow up on that study and examine clemastine fumarate's protective and reparative effects in the context of acute demyelinating brain lesions as imaged by multi-parametric MRI assessments. The investigators will be assessing the effects of clemastine fumarate as a remyelinating therapy and assessing its effect on MRI metrics of lesions found in patients with a confirmed diagnosis of acute inflammatory injury-causing demyelination. In addition to using conventional multi-parametric MRI assessments, this study will also evaluate a new MRI technique called Ultrashort Echo Time (UTE) MRI to assess the effects of clemastine fumarate as a remyelinating therapy of acute lesions found in patients with a confirmed diagnosis of acute inflammatory injury-causing demyelination and compare it to the other assessments.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55

44 Participants Needed

AURN001 for Corneal Edema

San Francisco, California
This trial is testing a new injection called AURN001 to help people with corneal swelling due to inner cornea problems. It aims to find out if AURN001 is safe and effective.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

GIM-122 for Advanced Solid Cancers

San Francisco, California
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

111 Participants Needed

Antibody-Drug Conjugate for Advanced Cancer

San Francisco, California
This trial is testing MBRC-101, a new drug, in patients with advanced cancers that haven't improved with other treatments. It aims to find the best dose and check its safety and effectiveness. The study will also observe how the drug behaves in the body and if it causes any immune reactions.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

130 Participants Needed

PER-001 for Diabetic Retinopathy

San Francisco, California
This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

24 Participants Needed

Vaporized Cannabis + Nicotine for Cannabis and Tobacco Use

San Francisco, California
This is a crossover, randomized, double-blinded clinical pharmacology study enrolling dual cannabis-tobacco smokers to better understand the combined effects of co-administering cannabis and tobacco. The project aims to describe the pharmacokinetics and pharmacodynamics of marijuana-tobacco co-administration by delivering THC and nicotine in various combinations. This foundational study will establish a research program focused on elucidating the public health consequences of marijuana-tobacco co-use.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 65

48 Participants Needed

64Cu-GRIP B PET Imaging for Genitourinary Cancer

San Francisco, California
This trial uses a special imaging technique to help see how well the immune system is fighting advanced GU cancers. It targets patients with specific types of advanced cancers and works by highlighting areas where immune cells are attacking cancer cells. This can help predict how well treatments are working.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

91 Participants Needed

TN-201 for Hypertrophic Cardiomyopathy

San Francisco, California
This trial tests a new drug, TN-201, in adults with a specific genetic heart condition. It aims to see if the drug is safe and how it affects their health over several years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

30 Participants Needed

TXA for Gender Affirming Mastectomy

San Francisco, California
Gender affirming surgeries (GAS) have been steadily increasing in the US, with the gender affirming mastectomy (GAM) being the most common surgery performed. Complications associated with these surgeries include hematoma and seroma. Prior studies in orthopedics, plastic surgery, and trauma have shown significant reduction of bleeding and ecchymosis with the use of tranexamic acid (TXA). TXA is a synthetic amino acid that blocks plasminogen conversion to plasmin, to stabilize clot formation. The intravenous (IV) efficacy in reducing hematoma rates has been established in implant-based breast reconstruction, as well as in reduction mammaplasty. However, there are currently no studies investigating the use of IV TXA in patients undergoing GAM. The investigators propose a single-center, prospective randomized control trial to evaluate the efficacy and safety of intravenous tranexamic acid in decreasing hematoma and seroma rates for top surgery patients at UCSF. Patients will be randomized into two groups, an experimental group receiving IV TXA and a control group that will not receive IV TXA. Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately following anesthesia induction. Patients will be excluded if they have a history of coagulopathy, bleeding disorders or prior chest surgery. Demographic data, surgical characteristics, and postoperative outcomes will also be recorded and analyzed. The investigators hypothesize that the use of IV TXA will significantly reduce hematoma, seroma, postoperative drain output, and time to drain removal in patients undergoing GAM. Aim 1: To evaluate the effectiveness of IV TXA in reducing intraoperative bleeding, post-operative hematoma and seroma formation, drain output, and time to drain removal in patients undergoing GAM. Aim 2: To compare the incidence of thromboembolic events and wound complications between patients receiving IV TXA and those who do not after GAM.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female

150 Participants Needed

Avutometinib + Defactinib + Chemotherapy for Pancreatic Cancer

San Francisco, California
This trial tests a new treatment combining two experimental drugs with two existing treatments for patients with newly diagnosed pancreatic cancer. The goal is to see if this combination can safely and effectively stop cancer growth and kill cancer cells. The study focuses on patients who have not yet received any treatment. One of the existing treatments used in the trial has been important in pancreatic cancer treatment but offers only modest improvements in symptoms and survival.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

40 Participants Needed

Hyperpolarized 13C-Pyruvate MRI for Solid Cancers

San Francisco, California
This is a single center prospective imaging study investigating the utility of hyperpolarized 13C-pyruvate +/-13C,15N-Urea/ metabolic MR imaging. The current protocol will serve as a companion imaging biomarker study paired with standard of care (SOC) therapeutics, as well as investigational therapies that participants may be scheduled to receive outside of this protocol.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

65 Participants Needed

PRO1184 for Cancer

Santa Rosa, California
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

569 Participants Needed

Siplizumab for Type 1 Diabetes

San Francisco, California
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites. The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM. The secondary objectives are to: 1. Assess the safety profile of siplizumab in recently diagnosed T1DM. 2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45

120 Participants Needed

TC-510 Cell Therapy for Cancer

San Francisco, California
This trial tests TC-510, a therapy using a patient's own modified T cells to target and attack cancer cells. It is aimed at patients with cancers that are hard to treat with standard methods. The modified T cells are designed to recognize specific proteins on cancer cells and get an extra boost to kill them.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

6 Participants Needed

Autologous Muscle Derived Cells for Swallowing Disorders

San Francisco, California
The primary objective of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety of AMDC-GIR during the 24 months following 2 consecutive treatments of tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or radiotherapy for squamous cell cancer of the oropharynx.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

66 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

ETX101 for Dravet Syndrome

San Francisco, California
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 47

22 Participants Needed

18F-OP-801 for ALS

San Francisco, California
This trial tests a new brain scan substance called 18F-OP-801 on patients with ALS, AD, MS, PD, and healthy volunteers. It helps doctors see brain inflammation by highlighting active immune cells. This could improve early detection and treatment of these diseases.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

65 Participants Needed

Avutometinib + Adagrasib for Lung Cancer

San Francisco, California
This trial is testing a combination of two drugs, avutometinib (VS-6766) and adagrasib, in patients with a specific type of lung cancer who have not responded to previous treatments. The drugs aim to stop the cancer cells from growing by blocking the signals that tell them to multiply. Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

85 Participants Needed

EAAT2 PET Tracer for Dementia

San Francisco, California
This trial tests a new imaging agent that can be seen with a PET scan to detect early brain changes in patients with Alzheimer's disease and frontotemporal dementia. The agent targets a specific brain protein that is less active in these diseases. By identifying these changes early, doctors hope to improve diagnosis and treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:40 - 75

102 Participants Needed

Blood Pressure Management Strategies for High Blood Pressure

San Francisco, California
This is a pilot randomized controlled trial which will test the effect of 3 different anti-hypertensive agents and 3 different strategies of engaging young adults in home blood pressure monitoring on blood pressure control, with secondary outcomes focused on quality of life and adverse events.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 40

120 Participants Needed

LAVA-1207 for Prostate Cancer

San Francisco, California
This trial tests new treatments for advanced prostate cancer that doesn't respond to standard treatments. The treatments include a new drug, an immune system booster, and a medication that helps the immune system fight cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Sex:Male

180 Participants Needed

Clemastine Fumarate for Multiple Sclerosis

San Francisco, California
This trial tests Clemastine Fumarate to see if it can repair myelin in patients with relapsing-remitting multiple sclerosis who have chronic brain lesions. The medication helps immature brain cells develop into myelin-producing cells, potentially fixing the damage caused by MS.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55

74 Participants Needed

Tafasitamab + Lenalidomide for CNS Lymphoma

San Francisco, California
This trial tests a combination of lenalidomide and Tafasitamab in patients with brain cancer that has returned after previous treatments. Lenalidomide, a derivative of thalidomide, is known to boost the immune system and directly target cancer cells, potentially improving drug delivery to the brain.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

35 Participants Needed

Psilocybin Therapy for Chronic Lower Back Pain

San Francisco, California
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur at UCSF. Each participant will receive a dose of psilocybin with possibly one or more other drugs. Participants will undergo two preparation sessions, a dosing session, three integration sessions to discuss their psilocybin experience, and several follow up sessions.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:25 - 70

30 Participants Needed

Tiragolumab + Atezolizumab for Solid Tumors

San Francisco, California
This trial studies how well tiragolumab and atezolizumab work in children and adults with difficult-to-treat tumors missing specific genes. These treatments help the immune system attack cancer and stop it from growing. Atezolizumab is an antibody that has been used with other treatments for various cancers.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+

86 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Honolulu, HI pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Honolulu, HI work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Honolulu, HI 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Honolulu, HI is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Honolulu, HI several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Honolulu, HI?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Honolulu, HI?

Most recently, we added LevoCept for Birth Control, Ipilimumab + Nivolumab with SBRT for Liver Cancer and SLS-002 for PTSD to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Hawaii

Anxiety Clinical Trials in Hawaii

Schizophrenia Clinical Trials in Hawaii

ADHD Clinical Trials in Hawaii

Bipolar Disorder Clinical Trials in Hawaii

Multiple Sclerosis Clinical Trials in Hawaii

Autism Clinical Trials in Hawaii

Treatment Resistant Depression Clinical Trials in Hawaii

Borderline Personality Disorder Clinical Trials in Hawaii

Social Anxiety Disorder Clinical Trials in Hawaii

Parkinson's Disease Clinical Trials in Hawaii

Alzheimer's Disease Clinical Trials in Hawaii

By Location

Clinical Trials near Honolulu, HI

Clinical Trials near ‘Aiea, HI

Clinical Trials near 'Aiea, HI

Clinical Trials near Lihue, HI

Clinical Trials near Aiea, HI

Clinical Trials near Wailuku, HI

Clinical Trials near Kailua, HI

Clinical Trials near ‘Ewa Beach, HI

Clinical Trials near 'Ewa Beach, HI

Clinical Trials near Kahului, HI

Clinical Trials near Hilo, HI

Clinical Trials near Tripler AMC, HI

Other People Viewed

By Subject

Top Clinical Trials near Honolulu, HI

Top Diabetes Clinical Trials near Honolulu, HI

Top Clinical Trials near Kailua, HI

Top Clinical Trials near Aiea, HI

Top Clinical Trials near Aiea, HI

Top Clinical Trials near Ewa Beach, HI

Top Clinical Trials near Kahului, HI

102 Clinical Trials near Wyoming

Top Clinical Trials near Oklahoma

Top Clinical Trials near Hawaii

Top Clinical Trials near Connecticut

Top Clinical Trials near Flossmoor, IL

By Trial

TracPatch Wearable Device for Knee Replacement Surgery Recovery

Fisetin for Frailty

Epidural Stimulation for Spinal Cord Injury

Mindfulness for Pain

Liraglutide for MODY

Rilzabrutinib for Immune Thrombocytopenia

Omega-3 fatty acid + Celecoxib for Breast Cancer

Venetoclax + Chemotherapy for B-Cell Lymphoma

CLBR001 CAR-T for Non-Hodgkin's Lymphoma

Machine Perfusion for Liver Transplant Preservation

Pemigatinib + Atezolizumab + Bevacizumab for Bile Duct Cancer

Lifestyle Intervention for Cancer Survivors

Related Searches

Top Clinical Trials near Ohio

Top Clinical Trials near Greensboro, NC

Top Clinical Trials near Colorado

Top Clinical Trials near Michigan

Top Amyotrophic-lateral-sclerosis Clinical Trials

Docetaxel + Radium 223 for Prostate Cancer

DF6002 + Nivolumab for Advanced Cancer

ETX-19477 for Cancer

Diet Intervention for Pregnancy Microbiome

HCV Positive Lung Transplant with Antiviral Therapy for Hepatitis C

Raludotatug Deruxtecan for Gastrointestinal Cancer

Prehabilitation for Postoperative Complications

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial